Baseline demographics, clinical characteristics, and treatment history of all RTX initiators. Values are n (%) or median (IQR) unless otherwise specified.
| Characteristics | All RTX Initiations, n = 376 | Ineligible, n = 111 | Eligible, n = 265 | p | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Demographics | ||||||||||
| Female | 301 (80.1) | 89 (80.2) | 212 (80.0) | 1.000 | ||||||
| White | 353 (93.9) | 99 (89.2) | 254 (95.9) | 0.019 | ||||||
| Age, yrs | 57 (50–65) | 59 (51–65) | 58 (50–65) | 0.641 | ||||||
| Non-RA comorbidity history, yrs | ||||||||||
| 0–1 | 279 (74.2) | 85 (76.6) | 194 (73.2) | 0.780 | ||||||
| 2–3 | 88 (23.4) | 24 (21.6) | 64 (24.2) | |||||||
| ≥ 4 | 9 (2.4) | 2 (1.8) | 7 (2.6) | |||||||
| Cancer | 52 (13.8) | 10 (9.0) | 42 (15.8) | 0.101 | ||||||
| Prognostic biomarkers | ||||||||||
| Anti-CCP–positive, n/N (%) | 61/86 (70.9) | 14/22 (63.6) | 47/64 (73.4) | 0.421 | ||||||
| RF-positive, n/N (%) | 183/238 (76.9) | 52/64 (81.3) | 131/174 (75.3) | 0.388 | ||||||
| Characteristics | n | Med | IQR | n | Med | IQR | n | Med | IQR | p |
| RA clinical characteristics | ||||||||||
| ARA class | 376 | 2 | 1–2 | 111 | 2 | 1–2 | 265 | 2 | 1–2 | 0.692 |
| Duration of RA, yrs | 374 | 13 | 6–21 | 111 | 12 | 5–19 | 263 | 13 | 7–22 | 0.259 |
| Prior medication use | ||||||||||
| No. prior DMARD | 376 | 2 | 1–3 | 111 | 2 | 1–3 | 265 | 2 | 1–3 | 0.299 |
| No. prior biologics | 376 | 2 | 1–3 | 111 | 2 | 1–3 | 265 | 2 | 1–3 | 0.073 |
| No. prior anti-TNF | 376 | 2 | 1–2 | 111 | 1 | 1–2 | 265 | 2 | 1–2 | 0.147 |
| No. prior non-anti-TNF biologics | 376 | 0 | 0–1 | 111 | 0 | 0–1 | 265 | 0 | 0–1 | 0.110 |
RTX: rituximab; IQR: interquartile range; RA: rheumatoid arthritis; anti-CCP: anticyclic citrullinated peptide antibodies; RF: rheumatoid factor; ARA: American Rheumatism Association; DMARD: disease-modifying antirheumatic drug; anti-TNF: anti-tumor necrosis factor.